Loading people...
Brian Liu is a Managing Director at Longitude Capital based in Menlo Park, California. Before joining the venture capital firm in 2018, he worked as an Engagement Manager at McKinsey & Company, where he specialized in the pharmaceuticals and medical products sectors. He holds a Doctor of Medicine from the Stanford School of Medicine and a Bachelor of Science in Biomedical Engineering from Johns Hopkins University. In his current capacity, he serves as a board director at CG Oncology and holds board observer roles at Quanta Therapeutics, Rivus Pharmaceuticals, and Zenas BioPharma. His previous investment experience includes board observerships at Talaris Therapeutics, Vera Therapeutics, and Inflazome prior to its acquisition by Roche. Liu leverages his clinical training and strategic consulting experience to focus on venture growth investments across the biotechnology, medical technology, and health solutions sectors.
Brian Liu is a distinguished Principal at Longitude Capital, a leading healthcare venture capital firm renowned for its strategic investments in the life sciences sector. In his pivotal role, Mr. Liu is instrumental in driving the firm's investment initiatives, from the initial identification of promising opportunities to the meticulous execution of deals and ongoing support for portfolio companies. His expertise is crucial in navigating the complex and rapidly evolving landscape of healthcare innovation.
At Longitude Capital, Brian Liu's investment focus aligns with the firm's core mission: backing groundbreaking companies that are poised to transform patient care and outcomes. This includes a broad spectrum of the life sciences, encompassing biotechnology, pharmaceuticals, medical devices, diagnostics, and health technology. He plays a key role in evaluating companies developing novel therapeutics, innovative medical technologies, and disruptive digital health solutions. His analytical rigor and deep industry insights are vital in assessing market potential, scientific validity, and the operational strengths of prospective investments.
Before joining Longitude Capital, Brian Liu cultivated a robust career foundation within the finance and healthcare industries. While specific details of his prior roles are not publicly detailed, professionals in his position typically bring a wealth of experience from areas such as investment banking, management consulting, or other venture capital firms specializing in healthcare. This background equips him with a comprehensive understanding of financial markets, corporate strategy, and the unique challenges and opportunities within the healthcare ecosystem. Such diverse experience is invaluable in identifying high-potential ventures and guiding them through various stages of growth.
As a Principal, Brian Liu contributes significantly to Longitude Capital's overall investment strategy and the success of its diverse portfolio. While individual deal attribution can be complex within a venture capital firm, his involvement spans across various stages of the investment lifecycle. He works closely with entrepreneurs and management teams, providing strategic guidance, operational support, and leveraging his network to help portfolio companies achieve their milestones. His commitment to fostering innovation and supporting the development of life-changing technologies underscores his dedication to the healthcare sector. Brian Liu's contributions help solidify Longitude Capital's position as a key player in advancing medical science and improving global health.
Brian Liu is a Principal at Longitude Capital, a prominent healthcare venture capital firm. He is actively involved in identifying, evaluating, and executing investment opportunities within the life sciences sector.
As part of Longitude Capital, Brian Liu invests in companies across the life sciences sector. This includes innovative firms in biotechnology, pharmaceuticals, medical devices, diagnostics, and health technology.
Brian Liu works as a Principal at Longitude Capital, a leading healthcare venture capital firm known for its investments in groundbreaking life sciences companies.
